首页> 外文期刊>Cell and tissue banking: An international journal of banking, engineering & transplantation of cells and tissues >A new standardized immunofluorescence method for potency quantification (SMPQ) of human conjunctival cell cultures
【24h】

A new standardized immunofluorescence method for potency quantification (SMPQ) of human conjunctival cell cultures

机译:一种新的人类结膜细胞培养物效力定量(SMPQ)的新标准化免疫荧光方法

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study is to set up a standardized and reproducible method to determine the potency (= stem cell content) of human conjunctival cell cultures by means of immunofluorescence-based analyses. This will help the development of new Advanced Therapy Medicinal Products (ATMPs) to use in future cell therapy clinical studies when fewer cells are available to perform the quality controls. To achieve this purpose, a reference standard was investigated and the expression levels of Delta Np63 alpha (considered as a marker of conjunctival stem cells) was correlated to cell size. The limbal hTERT cells were used as reference standard to define the expression value of Delta Np63 alpha. The mean intensity value of limbal hTERT cells ranging between 15 and 20 mu m in diameter was used to distinguish between Delta Np63 alpha bright and not bright cells. As Delta Np63 alpha bright expression was mainly seen in the smaller cell size group (10-15 mu m), we defined as conjunctival stem cells (= potency) those cells which were bright and with sizes between 10 and 15 mu m. Assays on cells from clonal analyses were used to validate the method, as they do allow to observe a decrease in potency (Holoclones > Meroclones > Paraclones). The stem cell content of conjunctival grafts was found to be 11.3% +/- 5.0 compared to 21.9% +/- 0.6, 9.0% +/- 8.1 and 0% from Holoclones, Meroclones and Paraclones, respectively. This new method, here named as Standardized Method for Potency Quantification, will allow to detect the potency in conjunctival cell cultures, thus obtaining a quality control assay responding to the GMP standards required for ATMP release.
机译:本研究的目的是建立一种标准化且可重复的方法,通过基于免疫荧光的分析测定人类结膜细胞培养物的效力(=干细胞含量)。这将有助于开发新的高级治疗药物产品(ATMPs),以便在未来的细胞治疗临床研究中,当可用于质量控制的细胞较少时使用。为了达到这一目的,研究了一种参考标准,并将Delta Np63α(视为结膜干细胞的标记物)的表达水平与细胞大小相关。以角膜缘hTERT细胞作为参考标准,确定Delta Np63α的表达值。使用直径在15到20μm之间的角膜缘hTERT细胞的平均强度值来区分Delta Np63α亮细胞和非亮细胞。由于Delta Np63α-bright表达主要见于较小的细胞大小组(10-15μm),我们将其定义为结膜干细胞(=潜能),即明亮且大小在10-15μm之间的细胞。克隆分析的细胞分析用于验证该方法,因为它们确实允许观察到潜能的降低(全克隆>梅洛克隆>副克隆)。结膜移植物的干细胞含量为11.3%+/-5.0,而全克隆、梅洛克隆和副克隆的干细胞含量分别为21.9%+/-0.6%、9.0%+/-8.1%和0%。这种新方法,这里称为效价定量标准化方法,将允许检测结膜细胞培养物中的效价,从而获得符合ATMP释放所需GMP标准的质量控制分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号